## IMACS FORM 07A: MYOSITIS DISEASE ACTIVITY ASSESSMENT TOOL (MDAAT) - 2005, VERSION 2

#### **General Guidelines for Completion:**

This is a combined tool that captures the physician's assessment of disease **activity** of various organ systems using (1) the 0-4 scale described below and (2) a visual analog scale (VAS). Please assess the clinical features (items 1-26) of each organ system based upon:

- a) The presence of clinical features or symptoms within the previous 4 weeks that are due to active disease (i.e. use your clinical judgment to determine how active the myositis-associated clinical feature has been within the previous 4 weeks)
- b) The judgment that the feature is due to the myositis disease process (i.e. clinical findings known or suspected to be due to another disease process or due to therapy should **NOT** be considered in this evaluation)
- c) The concept that disease activity is defined as a potentially reversible finding
- d) A clinical, functional, and laboratory assessment for each organ system:
  - NA = Cannot be assessed
  - 0 = Not present in the last 4 weeks
  - 1 = Improving clinically significant improvement in the last 4 weeks compared to the previous 4 weeks
  - 2 = The same manifestations that have been present for the last 4 weeks without significant improvement or deterioration compared to the previous 4 weeks
  - 3 = Worse clinically significant deterioration over the last 4 weeks compared to the previous 4 weeks
  - 4 = New in the last 4 weeks (compared to the previous 4 weeks)

Also, rate your overall (global) assessment of the ongoing disease activity over the past 4 weeks for each organ system on the 0-10cm VAS scale (which precedes the listed clinical features) by drawing a **vertical** mark on the 10cm line according to the following guidelines:

- left end of line = no evidence of disease activity
- midpoint of line = moderate disease activity
- right end of line = extreme or maximum disease activity

Please review the glossary as you score each listed clinical feature. The VAS score for each organ system integrates the severity of activity based upon all of the clinical features listed for that particular organ system.

# NOTE: The "Extramuscular Global Assessment" is very important as this is a Core Set Measure encompassing an overall evaluation for the disease activity in all the extramuscular organ systems and <u>excludes</u> muscle disease activity.

### Guidelines for scoring mild, moderate, severe:

First, identify the category of mild-severe **using the glossary as a guide**. Then score what has happened in the last 4 weeks compared to the previous 4 weeks. Note that with worsening (3) or new (4) activity in the designated category, the same degree of activity should be ascribed in the items that are "less severe." For example:

- In a patient developing <u>new</u> moderate muscle inflammation (see glossary for definition) in the last 4 weeks, "moderate muscle inflammation" (25b) would score a 4 as would "mild muscle inflammation" (25c)
- If "severe muscle inflammation" worsened in the last 4 weeks, then the severe (25a), moderate (25b) and mild (25c) muscle inflammation categories would <u>all</u> score a 3

If a patient had severe muscle inflammation at last visit one month ago and improves to a moderate category over the past 4 weeks (based on the glossary definition), then score the severe category (25a) as a 1 (improving) and score moderate (25b) and mild (25c) as either a 1 or 2 (this would depend on just how much improvement has occurred over the last month so the glossary should be reviewed for this). If one month later the symptoms have further improved, then score the severe category (25a) as a 0 and the moderate (25b) and mild (25c) categories as a 1.

## IMACS FORM 07a: MYOSITIS DISEASE ACTIVITY ASSESSMENT TOOL – 2005, Version 2

ASSESSOR:

Subject's IMACS number:

Constitutional Disease Activity	(Absent)	(Maximum)	Sev	<b>mples o</b> ere fatigi nd and a	ue or ma	alaise res	sulting ir	being bed
1. Pyrexia – documen	ted fever > 38° Celsius		0	1	2	3	4	NA
2. Weight loss – uninte	entional > 5%		0	1	2	3	4	NA
3. Fatigue/malaise/leth	nargy		0	1	2	3	4	NA
Cutaneous Disease Activity	(Absent)	(Maximum)	- Ulo	mples o ceration tensive e	to muscl	e, tendo	-	e;
4. Cutaneous ulceration	ภา		0	1	2	3	4	NA
5. Erythroderma			0	1	2	3	4	NA
6. Panniculitis			0	1	2	3	4	NA
7. Erythematous rashe	es:							
a. with secondary	changes (e.g. accompanied by erosions	, vesiculobullous change or necrosis)	0	1	2	3	4	NA
b. without second	ary changes		0	1	2	3	4	NA
8. Heliotrope rash			0	1	2	3	4	NA
9. Gottron's papules/s	ign		0	1	2	3	4	NA
10. Periungual capillary	changes		0	1	2	3	4	NA
11. Alopecia:								
a. Diffuse hair loss	3		0	1	2	3	4	NA
b. Focal, patchy w	ith erythema		0	1	2	3	4	NA
12. Mechanics hands			0	1	2	3	4	NA

Date Assessed:

Assessment number:

	(Absent) (N	laximum)			f maxim			
Skeletal		I			tis with e			unction
Disease Activity		cm	(bedr	idden, i	nability fo	or self ca	are)	
13. Arthritis:								
a. Severe active pol	yarthritis		0	1	2	3	4	NA
b. Moderately active	arthritis		0	1	2	3	4	NA
c. Mild arthritis			0	1	2	3	4	NA
14. Arthralgia			0	1	2	3	4	NA
Contraintenting	(Absent) (N	laximum)	Exan	ples of	f maxim	al score	•	
Gastrointestinal Disease Activity					ninal crisi	s requiri	ing surg	ery or
Discuse Adimy	· · · ·	' cm	intens	sive car	е			
15. Dysphagia:								
a. Moderate/severe	dysphagia		0	1	2	3	4	NA
b. Mild dysphagia			0	1	2	3	4	NA
16. Abdominal pain relat	ed to the myositis disease process:							
a. Severe			0	1	2	3	4	NA
b. Moderate			0	1	2	3	4	NA
c. Mild			0	1	2	3	4	NA
<b>_</b> .	(Absent) (N	laximum)	Exan	noles o	f maxim	al score	<b>}</b>	
Pulmonary Disease Activity			Active	e interst	itial lung	disease	or resp	
Disease Activity		۱ cm	musc	le weak	iness rec	uiring v	entilator	y support
17. Respiratory muscle	veakness without interstitial lung disease (ILD):							
a. Dyspnea at rest			0	1	2	3	4	NA
b. Dyspnea on exer	ion		0	1	2	3	4	NA
	D (i.e. not just ventilatory abnormalities due to pulmonary fibrosi							
	oring pulmonary function tests and score each item below (a,b a	ind c).			_	_		
a. Dyspnea or coug			0	1	2	3	4	NA
•	ormalities on chest x-ray or high resolution CT scan (HRCT) and	d/or	0	1	2	3	4	NA
ground glass sha	-							
•	on Tests: $\geq$ 10% change in FVC OR $\geq$ 15% change in DLCO		0	1	2	3	4	NA
19. Dysphonia:			•		0	0		N1.4
<ul> <li>a. Moderate to sev</li> <li>b. Mild</li> </ul>	ere		0 0	1 1	2 2	3 3	4 4	NA NA
D. WIIU			0	I	2	5	4	

IMACS Form 07a: Myositis Disease Activity Assessment Tool – 2005, Version 2, updated 2015

Cardiovascular Disease Activity	(Absent)	(Maximum)	) cm		rditis, p	ericardi	<b>al score</b> tis or se <sup>r</sup> re unit		nythmia
20. Pericarditis				0	1	2	3	4	NA
21. Myocarditis				0	1	2	3	4	NA
22. Arrhythmia:									
a. Severe arrhythmi	а			0	1	2	3	4	NA
b. Other arrhythmia,	, except sinus tachycardia			0	1	2	3	4	NA
23. Sinus tachycardia				0	1	2	3	4	NA

Other Disease Activity	(Absent)	(Maximum)	Extr	eme dis	of maxim ease act			mpact on
24. Specify:		 	0	1	2	3	4	NA
Extramuscular Global Assessment	(Absent)	 (Maximum)   cn	extra	amuscul	uation fo ar syster	ns		r in all CTIVITY)

Mussla Disessa	(Absent)	(Maximum)	Examples of maximal score
Muscle Disease		1	Severe muscle weakness resulting in being bed
Activity	Γ	cm	bound and an inability to perform self care

25. Myositis:

a. Severe muscle inflammation	0	1	2	3	4	NA
b. Moderate muscle inflammation	0	1	2	3	4	NA
c. Mild muscle inflammation	0	1	2	3	4	NA
26. Myalgia	0	1	2	3	4	NA

	(Absent)	(Maximum)	Overall evaluation for the totality of disease activity
Global Disease			in ALL systems, (INCLUDING MUSCLE DISEASE
Activity		cm	ACTIVITY)